The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation.

Albor C., Anyiam O., Boyle LD., Makaronidis J., Tan R., Iftikhar S., Burzic A., Lajeunesse Trempe F., Stanley M., Bhatti A., Scragg J., Badawy L., Moqeem K., Idris I., Andrews RC., Sen Gupta P., Hughes D., McCullough K., Tan T., McGowan B.

DOI

10.1007/s13679-026-00707-6

Type

Journal article

Publication Date

2026-04-02T00:00:00+00:00

Volume

15

Keywords

Asthma, CKD, Cancer, Cancer survival, Cardiovascular disease, Chronic kidney disease, Evidence review, GLP-1RA, Genetic obesity, Glucagon-like peptide-1 receptor agonist, Hidradenitis suppurativa, IIH, IVF, Idiopathic intracranial hypertension, In-vitro fertilisation, Liraglutide, MASH, MASLD, Metabolic dysfunction-associated steatotic liver disease, Metabolic-associated steatohepatitis, Mounjaro, OA, OSA, Obesity, Obesity pharmacotherapy, Obstructive sleep apnoea, Osteoarthritis, Overweight, PCOS, Polycystic ovary syndrome, Precancerous conditions, Psoriasis, Rare monogenic obesity, Saxenda, Semaglutide, Subfertility, T2DM, Tirzepatide, Transplant surgery, Type 2 diabetes, Wegovy

Permalink More information Close